Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Inclusion Criteria: * Previously histologically confirmed Hodgkin's lymphoma * Failure to achieve a complete remission with the initial induction chemotherapy, or recurrent disease * Performance status (ECOG) ≤ 3 * Age ≤ 75 years old * Number of prior chemotherapies: one or two regimens * At least one or more uni-dimensionally measurable lesion(s) defined as; ≥ 2 cm by conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination * Adequate organ functions defined as; ANC \> 1,500/ul, platelet \> 75,000/ul, transaminases \< 3 X upper normal values; bilirubin \< 2 mg/dL * Written informed consent approved by institutional review board or ethic committee Exclusion Criteria: * Previous high dose chemotherapy with autologous stem cell transplantation or allogeneic stem cell transplantation * Previous chemotherapies with ESHAP regimen * Any other malignancies within the past 5 years except skin basal cell carcinoma or carcinoma in situ of cervix * Other serious illness or medical conditions * Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry * History of significant neurologic or psychiatric disorders including dementia or seizures * Active uncontrolled infection (viral, bacterial or fungal infection) * Other serious medical illnesses * Pregnancy or breast-feeding, women of childbearing potential not employing adequate contraception * Previous history of drug allergy to one of the drugs in the study regimen